Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.36 |
| ▸ | ADH1C | P00326 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10251781 | 0.98 | ADH1A (0.39) | ADH1AADH1CADH1BCYP1A2CYP2D6 | |
| SCHEMBL25701346 | 0.91 | MAPT (0.32) | — | |
| SCHEMBL27420655 | 0.86 | ADH1A (0.37) | ADH1AADH1CADH1BALDH1A1 | |
| SCHEMBL27420648 | 0.85 | ADH1B (0.31) | ADH1AADH1CADH1B | |
| SCHEMBL25775271 | 0.83 | SLC29A1 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL17914491 | 0.80 | ADH1A (0.45) | ADH1AADH1CADH1B | |
| SCHEMBL4382413 | 0.78 | ADH1A (0.36) | ADH1AADH1CADH1B | |
| SCHEMBL736236 | 0.78 | ADH1A (0.36) | ADH1AADH1CADH1B | |
| SCHEMBL27420646 | 0.78 | — | — | |
| SCHEMBL9927917 | 0.78 | ADH1A (0.41) | ADH1AADH1CADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218816-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | ADH1A 2548/4885ADH1C 3254/4885ADH1B 2478/4885 |
| US-20220218816-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SARS1, POLRMT, SARNP | ADH1A 3621/4885ADH1C 3825/4885ADH1B 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.